Cardiac Marker Testing Market to exceed USD 18.4 billion by 2032, Says Graphical Research Powered by GMI

Cardiac marker testing industry is anticipated to register 7.6% CAGR between 2023 and 2032 due to increasing government initiatives for the diagnosis of cardiac diseases.

Selbyville, Delaware, May 30, 2023 (GLOBE NEWSWIRE) —

Cardiac Marker Testing Market size will surpass USD 18.4 billion by 2032. The rising prevalence of cardiovascular diseases will boost the cardiac marker testing industry growth. Another driver fueling the gains of the market is the rapidly aging global population. As people age, their risk of developing CVD increases, resulting in a greater demand for cardiac marker testing.

Request for a sample of this research report @

New developments in portable POC analyzers will drive industry revenue

The market is bifurcated into analyzers and consumables. The demand for analyzers will increase substantially over 2032 as they provide accurate and rapid results for various cardiac markers, including troponin, myoglobin, and creatine kinase-MB (CK-MB). These markers are essential in diagnosing acute myocardial infarction (AMI) and other cardiovascular diseases. The growing demand for efficient and reliable diagnostic tools has resulted in the development of advanced analyzers, which offer enhanced sensitivity and specificity.

Growing demand for early diagnostic markers in myoglobin testing
With regards to biomarker type, the cardiac marker testing market is segmented into Troponins, Myoglobin, Creatine kinase (CK-MB), Brain Natriuretic Peptide (BNP), Ischemia Modified Albumin (IMA).  Market share from myoglobin will register significant progress over 2032. Myoglobin is a vital cardiac marker that plays a significant role in the early diagnosis of myocardial infarction. Levels of this heme protein, found in cardiac and skeletal muscle cells, rise rapidly following myocardial injury.

Browse key industry insights spread across 280 pages with 510 market data tables & 19 figures & charts from the report, “Cardiac Marker Testing Market Size By Product (Consumables, Analyzers), By Biomarker Type (Troponins, Myoglobin, Creatine kinase (CK-MB), Brain Natriuretic Peptide (BNP), Ischemia Modified Albumin (IMA)), By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis), By Distribution Channel (Hospital Pharmacies, Brick & Mortar, E-commerce), By End-use (Hospitals, Diagnostic Centers) & Forecast, 2023 – 2032” In detail along with the table of contents:

Myoglobin is released into the bloodstream within 2-3 hours of acute myocardial infarction (AMI), making it a valuable early diagnostic marker. Myoglobin testing offers a myriad of benefits including better prognostic value, early detection, and complementary marker. Additionally, when used in conjunction with other cardiac markers such as troponin and CK-MB, it can improve diagnostic accuracy and risk stratification, which will further amplify demand for testing of these cardiac biomarkers.

Europe to emerge as a hotspot for cardiac marker testing
Europe cardiac marker testing market will exhibit robust expansion over 2032, led by the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and growing awareness about the benefits of early diagnosis. The use of analyzers and other advanced diagnostic tools has gained momentum in the region, contributing to higher demand for cardiac marker testing. The population of elderly people is also increasing rapidly across Europe, increasing the risk of CVDs.

Secure a copy of the premium research report @

Cardiac marker testing market competitive landscape

Abbott, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Inc., Creative Diagnostics, and Danaher Corporation are some of the leading players in the global cardiac marker testing industry.

Partial Table of Contents (ToC) of the report:

Chapter 3   Cardiac Marker Testing Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers   Growing prevalence of cardiovascular diseases   Technological advancements   Increasing funding from public and private organizations for R&D   Rising demand for point-of-care (POC) testing   Increasing government initiatives for the diagnosis of cardiac diseases

3.2.2    Industry pitfalls & challenges   Stringent regulatory frameworks   Lack of skilled professionals   Availability of substitute product

3.3    Growth potential analysis

3.3.1    By product

3.3.2    By biomarker type

3.3.3    By application

3.3.4    By distribution channel

3.3.5    By end use

3.4    COVID- 19 impact analysis

3.5    Pricing analysis, 2022

3.6    Regulatory landscape

3.6.1    U.S.

3.6.2    Europe

3.7    Technology landscape

3.8    Future market trends

3.9    Gap analysis

3.10    Porter’s analysis

3.11    PESTEL analysis

Browse Our Reports Store – GMIPulse @

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

CONTACT: Contact Us: Aashit Tiwari Corporate Sales, USA Global Market Insights Inc. Toll Free: +1-888-689-0688 USA: +1-302-846-7766 Europe: +44-742-759-8484 APAC: +65-3129-7718 Email: [email protected]

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.